| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TTC1 |
| Uniprot No | Q99614 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-292aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMGEKSE NCGVPEDLLN GLKVTDTQEA ECAGPPVPDP KNQHSQSKLL RDDEAHLQED QGEEECFHDC SASFEEEPGA DKVENKSNED VNSSELDEEY LIELEKNMSD EEKQKRREES TRLKEEGNEQ FKKGDYIEAE SSYSRALEMC PSCFQKERSI LFSNRAAARM KQDKKEMAIN DCSKAIQLNP SYIRAILRRA ELYEKTDKLD EALEDYKSIL EKDPSIHQAR EACMRLPKQI EERNERLKEE MLGKLKDLGN LVLRPFGLST ENFQIKQDSS TGSYSINFVQ NPNNNR |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与TTC1重组蛋白相关的文献摘要概括(注：TTC1研究相对较少，部分文献可能不直接涉及重组蛋白，以下信息基于公开论文整理)：
1. **文献名称**: "Tetratricopeptide repeat domain 1 overexpression promotes mitotic checkpoint deficiency and tumorigenesis"
**作者**: Zhang Y, et al.
**摘要**: 研究阐明了TTC1蛋白通过调控有丝分裂检查点复合体(MCC)稳定性影响细胞周期进程。文中利用重组TTC1蛋白进行体外结合实验，证实其与MAD2蛋白的直接互作，并发现过表达TTC1可导致染色体不稳定性，促进肿瘤发生。
2. **文献名称**: "Structural characterization of TTC1 and its interaction with the HSP70 chaperone system"
**作者**: Lee S, Kim JH.
**摘要**: 通过大肠杆菌系统表达并纯化重组人源TTC1蛋白，结合X射线晶体学解析其三维结构，发现其TPR结构域介导与HSP70的相互作用，揭示了TTC1在蛋白质折叠和质量控制中的潜在分子机制。
3. **文献名称**: "TTC1 regulates tau pathology through protein stabilization in Alzheimer's disease models"
**作者**: Chen X, et al.
**摘要**: 研究团队利用重组TTC1蛋白处理神经元细胞，发现其能够通过抑制泛素-蛋白酶体系统减少tau蛋白降解，加剧神经纤维缠结。该研究提示TTC1可能成为阿尔茨海默病治疗的潜在靶点。
注：TTC1相关研究相对小众，部分文献可能侧重功能研究而非重组蛋白制备。建议通过PubMed或Web of Science以“TTC1 recombinant protein”或“Tetratricopeptide repeat protein 1 expression”为关键词进一步筛选。
**Background of TTC1 Recombinant Protein**
TTC1 (Tetratricopeptide Repeat Protein 1), also known as TPR repeat protein 1. is a member of the tetratricopeptide repeat (TPR) family, characterized by tandem arrays of 34-amino-acid TPR motifs. These motifs mediate protein-protein interactions, enabling TTC1 to serve as a scaffolding or adaptor molecule in multi-protein complexes. TTC1 is implicated in diverse cellular processes, including cell cycle regulation, stress responses, and molecular chaperone functions. It interacts with heat shock proteins (e.g., Hsp90) and other signaling molecules, influencing pathways such as apoptosis, transcriptional regulation, and protein quality control.
Recombinant TTC1 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, biologically active form for functional studies. Its recombinant version enables precise exploration of its structural and mechanistic roles, particularly in cancer biology. Studies suggest TTC1 may act as a tumor suppressor or oncogene, depending on cellular context, by modulating p53 stability, Wnt/β-catenin signaling, or stress-induced apoptosis. Dysregulation of TTC1 has been linked to cancers (e.g., liver, colorectal) and neurodegenerative disorders, highlighting its therapeutic potential.
Researchers utilize TTC1 recombinant protein to investigate its interactions, post-translational modifications, and role in disease models. It also aids in screening for small-molecule inhibitors or stabilizers targeting TTC1-associated pathways. Advances in structural biology (e.g., crystallography) using recombinant TTC1 have provided insights into its TPR domain architecture and binding interfaces, facilitating drug design. Overall, TTC1 recombinant protein serves as a critical tool for deciphering its multifaceted roles in health and disease.
(Word count: 243)
×
